Compare KOP & AURA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | KOP | AURA |
|---|---|---|
| Founded | 1988 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Forest Products | Biotechnology: Pharmaceutical Preparations |
| Sector | Basic Materials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 784.7M | 631.6M |
| IPO Year | 2005 | 2021 |
| Metric | KOP | AURA |
|---|---|---|
| Price | $30.18 | $6.57 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 6 |
| Target Price | ★ $56.00 | $16.60 |
| AVG Volume (30 Days) | 127.2K | ★ 854.5K |
| Earning Date | 11-06-2026 | 11-16-2026 |
| Dividend Yield | ★ 0.91% | N/A |
| EPS Growth | ★ 11.38 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $1,879,300,000.00 | N/A |
| Revenue This Year | $2.85 | N/A |
| Revenue Next Year | $4.53 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $26.02 | $4.73 |
| 52 Week High | $53.00 | $9.54 |
| Indicator | KOP | AURA |
|---|---|---|
| Relative Strength Index (RSI) | 20.57 | 53.85 |
| Support Level | N/A | $6.04 |
| Resistance Level | $39.19 | $6.90 |
| Average True Range (ATR) | 1.87 | 0.32 |
| MACD | -0.47 | 0.04 |
| Stochastic Oscillator | 33.61 | 76.97 |
Koppers Holdings Inc through its subsidiaries, manufactures and sells wood products, wood treatment chemicals, and carbon compounds used in markets such as railroad, aluminum and steel, agriculture, utilities, and residential lumber. The company is organized into three business segments: railroad and utility products and services, performance chemicals, and carbon materials and chemicals. Its product portfolio includes treated and untreated wood products like crossties used in railroads, wood preservation chemicals, and carbon compounds such as creosote used in the treatment of wood crossties, among others. The majority of its revenue comes from the company's railroad and utility products and services segment, and more than half of the company's revenue is earned in the United States.
Aura Biosciences Inc is a clinical-stage biotechnology company developing precision immunotherapies to treat a range of solid tumors designed to preserve the function of organs afflicted with cancer. Its candidate bel-sar is in late-stage clinical development for the treatment of patients with primary choroidal melanoma, and other ocular oncology indications as well as in early-stage clinical development in bladder cancer. The Company views its operations and manages its business in one operating segment operating exclusively in the United States.